Antinuclear antibody positivity in patients with chronic hepatitis C: Clinically relevant or an epiphenomenon?

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 4, 2009, Pages 350-356

  Narciso Schiavon, Janaína L ^a   Freire, Fernanda Caruso F ^a   Suarez, Marcelo Mendes ^a   Ferrari, Marcus Vinícius O ^a   Scanhola, Gustavo Quirino ^a   De Lucca Schiavon, Leonardo ^a   Carvalho Filho, Roberto J de ^a   Ferraz, Maria Lucia G ^a   Silva, Antonio Eduardo B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hepatitis C; Interferon alfa; Keywordsantinuclear antibodies; Ribavirin; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON;

ADULT; ARTICLE; BIOPSY; BLOOD; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS C; HUMAN; IMMUNOLOGY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; CLINICAL FEATURE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN TISSUE; IMMUNOFLUORESCENCE; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES, ANTINUCLEAR; ANTIVIRAL AGENTS; BIOPSY; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; INTERFERON-ALPHA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 67649615876     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283089392     Document Type: Article

References (33)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
2. McMurray RW, Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 1997; 26:689-701.
3. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006; 43:S132-S144.
4. Strassburg CP, Vogel A, Manns MP. Autoimmunity and hepatitis C. Autoimmun Rev 2003; 2:322-331.
5. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55:1350-1359.
6. Sezaki H, Arase Y, Tsubota A, Suzuki Y, Kobayashi M, Saitoh S, et al. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol 2003; 38:493-500.
7. Yee LJ, Kelleher P, Goldin RD, Marshall S, Thomas HC, Alberti A, et al. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat 2004; 11:459-464.
8. Wasmuth HE, Stolte C, Geier A, Dietrich CG, Gartung C, Lorenzen J, et al. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004; 4:4.
9. Gatselis NK, Georgiadou SP, Koukoulis GK, Tassopoulos N, Zachou K, Liaskos C, et al. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther 2006; 24:1563-1573.
10. Stroffolini T, Colloredo G, Gaeta GB, Sonzogni A, Angeletti S, Marignani M, et al. Does an ‘autoimmune’ profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. J Viral Hepat 2004; 11:257-262.
11. Muratori P, Muratori L, Guidi M, Granito A, Susca M, Lenzi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40:501-507.
12. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26:561-566.
13. Noda K, Enomoto N, Arai K, Masuda E, Yamada Y, Suzuki K, et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol 1996; 31:716-722.
14. Wada M, Kang KB, Kinugasa A, Shintani S, Sawada K, Nishigami T, et al. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C? Intern Med 1997; 36:248-254.
15. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
16. Zauli D, Cassani F, Bianchi FB. Auto-antibodies in hepatitis C. Biomed Pharmacother 1999; 53:234-241.
17. Fried MW, Draguesku JO, Shindo M, Simpson LH, Banks SM, Hoofnagle JH, et al. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci 1993; 38:631-636.
18. Baig MM, Shere SJ. Prevalence of autoantibodies in Saudi population. J Med 1989; 20:286-290.
19. Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987; 69:557-565.
20. Goemaere S, Ackerman C, Goethals K, De Keyser F, Van der Straeten C, Verbruggen G, et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990; 17:1620-1622.
21. Azizah MR, Shahnaz M, Zulkifli MN, Nasuruddin BA. Anti-nuclear, anti-mitochondrial, anti-smooth muscle and anti-parietal cell antibodies in the healthy Malaysian population. Malays J Pathol 1995; 17:83-86.
22. Peng YC, Hsieh SC, Yang DY, Tung CF, Hu WH, Huang WN, et al. Expression and clinical significance of antinuclear antibody in hepatitis C virus infection. J Clin Gastroenterol 2001; 33:402-406.
23. Zusinaite E, Metskula K, Salupere R. Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia. World J Gastroenterol 2005; 11:488-491.
24. Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107:200-207.
25. Pockros PJ, Tong M, Lee WM, van Leeuwen DJ, Keeffe EB, Bala K, et al. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group. J Viral Hepat 1998; 5:271-276.
26. Everson GT, Jensen DM, Craig JR, van Leeuwen DJ, Bain VG, Ehrinpreis MN, et al. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology 1999; 30:271-276.
27. Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 1999; 94:3583-3588.
28. Blatt LM, Tong MJ, McHutchison JG, Russell J, Schmid P, Conrad A. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers. J Interferon Cytokine Res 1998; 18:75-80.
29. Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003; 38:509-517.
30. Schiano TD, Te HS, Thomas RM, Hussain H, Bond K, Black M. Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome. Am J Gastroenterol 2001; 96:2984-2991.
31. Hano H, Takasaki S, Nakayama J. Autoimmune forms of chronic hepatitis associated with hepatitis C virus (HCV) infection with and without HCV-RNA: histological differences from pure autoimmune hepatitis and chronic hepatitis C. Pathol Int 2000; 50:106-112.
32. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31:929-938.
33. Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006; 101:2360-2378.